Hormone research最新文献_第8页

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-01-21 DOI: 10.1159/000178029

Robert M Carey

{"title":"Primary aldosteronism.","authors":"Robert M Carey","doi":"10.1159/000178029","DOIUrl":"https://doi.org/10.1159/000178029","url":null,"abstract":"Background: Hypertension is one of the world’s leading risk factors for morbidity and mortality. Most affected individuals have primary hypertension, while the most common cause of secondary hypertension is primary aldosteronism (6–10%). Primary Aldosteronism: Clinical manifestations include hypertension, hypokalemic alkalosis, renal dysfunction, nephrogenic diabetes insipidus, muscle weakness, paresthesias, tetany and, in severe cases, paralysis. The cardiovascular risks for patients with primary aldosteronism are greater than those for patients with primary hypertension. Compared with normotensive subjects, patients with primary aldosteronism have a 4.2-fold greater risk of stroke, a 6.5-fold greater risk of myocardial infarction and a 12.1-fold greater risk of atrial fibrillation. Diagnosis: Patients with hypertension are screened for primary aldosteronism based on the plasma aldosterone to plasma renin activity ratio. A value >30 constitutes a positive result. The diagnosis must be confirmed using one of four available aldosterone suppression tests. Lateralization of aldosterone hypersecretion is documented by adrenal venous sampling. Management: The foundation of primary aldosteronism management is normalization of circulating aldosterone and/or mineralocorticoid blockade. Optimal treatment of unilateral disease is adrenalectomy; spironolactone is the treatment of choice for bilateral disease.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"71 Suppl 1 ","pages":"8 - 12"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000178029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27932278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Is epigenetics an important link between early life events and adult disease? 表观遗传学是早期生活事件和成年疾病之间的重要联系吗?

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-01-21 DOI: 10.1159/000178030

Robert A Waterland

引用次数: 144

Recent challenges in the diagnosis of Cushing's syndrome. 库欣综合征诊断的最新挑战。

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-01-21 DOI: 10.1159/000178053

Francesca Pecori Giraldi

{"title":"Recent challenges in the diagnosis of Cushing's syndrome.","authors":"Francesca Pecori Giraldi","doi":"10.1159/000178053","DOIUrl":"https://doi.org/10.1159/000178053","url":null,"abstract":"Background: The diagnosis of Cushing's syndrome still represents a challenge for the endocrinologist. Correct implementation and interpretation of diagnostic procedures require expertise and a high degree of clinical knowledge. The diagnosis should be established based on results of two or more concordant first-line tests (e.g., urinary free cortisol, midnight serum cortisol and low-dose dexamethasone testing); otherwise, second-line tests such as the dexamethasone-suppressed corticotrophin-releasing hormone (CRH) test, desmopressin stimulation or later reevaluation can confirm/exclude the diagnosis. Aetiological diagnosis requires measurement of plasma corticotrophin (ACTH) to distinguish between ACTH-dependent (pituitary or extrapituitary ACTH-secreting tumors) and ACTH-independent Cushing's syndrome (adrenal cortisol-secreting lesions), and the possible detection of normal ACTH levels in patients with adrenal Cushing's syndrome must be kept in mind. Lastly, the differential diagnosis between pituitary and ectopic ACTH secretion can be performed using CRH testing, high-dose dexamethasone suppression and inferior petrosal sinus sampling.Conclusions: The different epidemiology of the two entities and the incomplete diagnostic accuracy of diagnostic procedures mandate careful evaluation of test results.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"71 Suppl 1 ","pages":"123-7"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000178053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27933133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Longitudinal evaluation of patients with a homozygous R450H mutation of the TSH receptor gene. TSH受体基因纯合子R450H突变患者的纵向评估。

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-06-06 DOI: 10.1159/000223415

Haruo Mizuno, Keisuke Kanda, Yukari Sugiyama, Hiroki Imamine, Tetsuya Ito, Ineko Kato, Hajime Togari, Tomohiro Kamoda, Kazumichi Onigata

{"title":"Longitudinal evaluation of patients with a homozygous R450H mutation of the TSH receptor gene.","authors":"Haruo Mizuno, Keisuke Kanda, Yukari Sugiyama, Hiroki Imamine, Tetsuya Ito, Ineko Kato, Hajime Togari, Tomohiro Kamoda, Kazumichi Onigata","doi":"10.1159/000223415","DOIUrl":"https://doi.org/10.1159/000223415","url":null,"abstract":"Background/aim: The R450H mutation of the TSH receptor (TSHR) gene has been frequently observed in Japanese patients with resistance to TSH. The purpose of this study was to clarify the phenotype of patients with a homozygous R450H mutation of the TSHR gene; the mutant receptor has previously demonstrated moderately impaired function in vitro.Methods: We performed a clinical investigation of 5 Japanese patients who had hyperthyrotropinemia as neonates, in whom a homozygous R450H mutation of the TSHR gene had been demonstrated by genetic sequencing analysis.Results: The thyroid hormone levels of the patients were normal in early infancy, although their serum levels of TSH were mildly elevated. After supplemental treatment with levothyroxine sodium (L-T4) was started, we had to increase the dose to maintain the level of TSH within the normal range in all patients. Thyroid dysfunction became obvious in one patient at reexamination during adolescence when L-T4 treatment was stopped for 1 month. Four patients were examined for intelligence quotient and their scores were normal.Conclusions: Thyroid hormone replacement therapy should be considered based on biological data in patients with hyperthyrotropinemia who have a homozygous R450H mutation of the TSHR gene even if they do not exhibit obvious hypothyroidism in infancy.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"71 6","pages":"318-23"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000223415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28228237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Birth size, postnatal growth and growth during growth hormone treatment in small-for-gestational-age children: associations with IGF1 gene polymorphisms and haplotypes? 小胎龄儿童的出生尺寸、出生后生长和生长激素治疗期间的生长:与IGF1基因多态性和单倍型的关系?

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-06-30 DOI: 10.1159/000224336

Wietske A Ester, Joyce B van Meurs, Nicolette J Arends, André G Uitterlinden, Maria A de Ridder, Anita C Hokken-Koelega

{"title":"Birth size, postnatal growth and growth during growth hormone treatment in small-for-gestational-age children: associations with IGF1 gene polymorphisms and haplotypes?","authors":"Wietske A Ester, Joyce B van Meurs, Nicolette J Arends, André G Uitterlinden, Maria A de Ridder, Anita C Hokken-Koelega","doi":"10.1159/000224336","DOIUrl":"https://doi.org/10.1159/000224336","url":null,"abstract":"Background: Short small-for-gestational-age (SGA) children experience pre- and postnatal growth restriction, which might be influenced by polymorphisms in the IGF1 gene. The well-known -841(CA)(n)/192 bp polymorphism has been associated with birth size and cardiovascular disease.Aims: To determine whether birth size, postnatal growth and growth during growth hormone (GH) treatment, were associated with IGF1 gene polymorphisms and haplotypes.Methods: 201 short SGA children were investigated for four IGF1 gene polymorphisms in the promoter (-G1245A, -841(CA)(n)), intron 2 (+3703(CT)(n)) and 3UTR (+A1830G). Spontaneous growth and growth during GH treatment were studied.Results: The -1245 A allele was identified as a marker-allele for the well-known -841(CA)(n)/non-192 bp allele, both part of haplotype 2. The -1245 A allele was not associated with head circumference at birth, but was associated with a postnatal 0.3 SDS smaller head circumference at age 1-3. The -1245 A allele was also associated with a 1-week shorter gestational age which explained the association with a smaller absolute birth size. No associations were found with gestational age-adjusted birth size, height and weight SDS during postnatal life and with growth during GH treatment.Conclusions: The -G1245A SNP appeared to be a marker for the well-known -841(CA)(n)/192 bp polymorphism. Haplotype 2, of which the -1245 A allele was the marker, was associated with a smaller head circumference SDS during spontaneous postnatal growth, but not during GH treatment.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"72 1","pages":"15-24"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000224336","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28356075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Dose-dependent effects of triiodothyronine on the osteogenic differentiation of rat bone marrow mesenchymal stem cells. 三碘甲状腺原氨酸对大鼠骨髓间充质干细胞成骨分化的剂量依赖性影响。

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-08-18 DOI: 10.1159/000232161

J N Boeloni, N M Ocarino, A B Melo, J F Silva, P Castanheira, A M Goes, R Serakides

{"title":"Dose-dependent effects of triiodothyronine on the osteogenic differentiation of rat bone marrow mesenchymal stem cells.","authors":"J N Boeloni, N M Ocarino, A B Melo, J F Silva, P Castanheira, A M Goes, R Serakides","doi":"10.1159/000232161","DOIUrl":"https://doi.org/10.1159/000232161","url":null,"abstract":"Background/aims: The aim of this study was to investigate the dose-dependent effects of triiodothyronine (T3) on the osteogenic differentiation of mesenchymal stem cells(MSCs).Methods: MSCs that express CD73, CD54 (intercellular adhesion molecule-1) and CD90 were cultured in triplicate (1 x 10(5)/well) in osteogenic medium with T3 (1, 10, 10(3) or 10(5) pM) or without T3 (control) for 7, 14 and 21 days. Alkaline phosphatase activity, conversion of MTT into formazan crystals, collagen synthesis, collagen maturation, the number of mineralized nodules and their diameters were all determined, and the means were compared by the Student-Newman-Keuls test.Results: A dose of 10(5) pM T3 resulted in a negative effect on MSC osteogenic differentiation, with less collagen synthesis. The 1 pM T3 dose resulted in greater collagen synthesis and alkaline phosphatase activity and more mineralized nodules than in the control group, similar to the 10 pM dose. Nevertheless, the 10 pM dose demonstrated better results than the 1 pM dose with regard to MSC osteogenic differentiation, with greater MTT reduction, better collagen maturation and a larger mean diameter of mineralized nodules.Conclusions: The effect of T3 on MSC differentiation is dose-dependent, with the 10 pM dose promoting better bone marrow MSC osteogenic differentiation.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"72 2","pages":"88-97"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000232161","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28347844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Episodic spontaneous hypothermia potentially triggered by hyperinsulinemia. 可能由高胰岛素血症引起的偶发性自发性体温过低。

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-08-18 DOI: 10.1159/000232166

R Capanna, M L Marcovecchio, A Verrotti, D Trotta, F Chiarelli, A Mohn

{"title":"Episodic spontaneous hypothermia potentially triggered by hyperinsulinemia.","authors":"R Capanna, M L Marcovecchio, A Verrotti, D Trotta, F Chiarelli, A Mohn","doi":"10.1159/000232166","DOIUrl":"https://doi.org/10.1159/000232166","url":null,"abstract":"Episodic spontaneous hypothermia is an infrequent disorder, the pathogenic mechanisms of which have not been completely clarified, although alterations in the serotoninergic system have been suggested. We report the history of a girl with episodes of dizziness and shivering associated with a body temperature lower than 35 degrees C since the age of 10 months. At the age of 11 years, she was admitted to a local hospital and an oral glucose tolerance test showed high total insulin levels. Hypoglycemia secondary to hyperinsulinemia was suspected, and a low-carbohydrate (simple) diet was proposed without results. Due to the recurrence of the episodes, episodic spontaneous hypothermia triggered by hyperinsulinemia was suspected, and treatment with flunarizine, a drug considered the first line in the treatment of migraine-related disorders, was started with a resulting reduction in the episodes. A new endocrinological evaluation showed decreased insulin secretion. In our patient, the success of the therapy might be due to the well-known effect of calcium antagonists in inhibiting serotonin uptake and thereby regulating serotonin levels after hyperinsulinism. This case suggests hyperinsulinemia as a potential mechanism for episodic spontaneous hypothermia, probably mediated by an interaction between insulin and the serotoninergic system.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"72 2","pages":"124-8"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000232166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28349369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Puberty and ovarian function in girls with type 1 diabetes mellitus. 1型糖尿病女孩青春期与卵巢功能的关系。

Hormone research Pub Date : 2009-01-01 Epub Date: 2008-11-27 DOI: 10.1159/000173737

Ethel Codner, Fernando Cassorla

{"title":"Puberty and ovarian function in girls with type 1 diabetes mellitus.","authors":"Ethel Codner, Fernando Cassorla","doi":"10.1159/000173737","DOIUrl":"https://doi.org/10.1159/000173737","url":null,"abstract":"Insulin is well known for its effects on carbohydrate metabolism, but this hormone also plays an important role in regulating ovarian function. Granulosa, theca and stromal ovarian cells may be affected by insulin deficiency or excess, which may be present in women with type 1 diabetes mellitus (T1D). Recent publications have shown that in spite of intensive insulin therapy, some delay in the age of thelarche, pubarche and menarche is still observed in girls with T1D. In addition, ovarian hyperandrogenism may be observed during late adolescence and an increased prevalence of hirsutism and polycystic ovarian syndrome (PCOS) has been described in adult women with T1D. These endocrine abnormalities may be related to nonphysiologic insulin replacement therapy and to hyperglycemia. This paper reviews the pubertal development and the clinical reproductive abnormalities observed in girls with type 1 diabetes mellitus, and shows that several significant clinical problems, such as pubertal delay, menstrual disturbances and hyperandrogenism which may ultimately lead to the development of PCOS in adulthood, may be observed in some of these patients.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"71 1","pages":"12-21"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000173737","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27863977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 71

Monogenic and polygenic models detected in steroid 21-hydroxylase deficiency-related paediatric hyperandrogenism. 类固醇21-羟化酶缺乏相关的儿童高雄激素症的单基因和多基因模型检测。

Hormone research Pub Date : 2009-01-01 Epub Date: 2008-11-27 DOI: 10.1159/000173739

B Ezquieta, M Oyarzabal, R Barrio, C Luzuriaga, F Hermoso, J L Lechuga, S Quinteiro, A Rodríguez, J I Labarta, A Gutierrez Macias, M Gallego, J M Bellón

{"title":"Monogenic and polygenic models detected in steroid 21-hydroxylase deficiency-related paediatric hyperandrogenism.","authors":"B Ezquieta, M Oyarzabal, R Barrio, C Luzuriaga, F Hermoso, J L Lechuga, S Quinteiro, A Rodríguez, J I Labarta, A Gutierrez Macias, M Gallego, J M Bellón","doi":"10.1159/000173739","DOIUrl":"https://doi.org/10.1159/000173739","url":null,"abstract":"Aims: Hyperandrogenism, although mostly due to polygenic interactions, is monogenic for some enzymatic adrenal deficiencies. This study evaluates mono- and biallelic 21-hydroxylase deficiency (21OHD)-related hyperandrogenism in pediatric patients. Sensitizing and protective polymorphisms were investigated in carriers and cryptic forms of 21OHD.Methods: The study involved a monogenic analysis of CYP21A2 in patients (375 nonclassical 21OHD [NC21OHD] children; 306 hyperandrogenic 21OHD carriers, n = 306) and a polygenic association study (CAPN10-UCSNP44, PON1-108, TNFR2-M196R, IGF2-ApaI and IRS1-G972R polymorphisms) of 170 hyperandrogenic carriers plus 277 family members (control groups). The metabolic marker 17OH progesterone defined the degree of deficiency; clinical expressivity was determined by pediatric endocrinologists.Results: The group of 21OHD carriers manifesting hyperandrogenism was enriched in the CAPN-UCSNP44 rare variant in homozygosity (4.9 vs. 0.4%, NCBI data for the general population; p = 0.004). In our patients and controls, contrasting distributions were observed for this and another polymorphism, TNFR2-196R. In a recessive model, their rare variants were more frequently detected among the forms with high (p = 0.048) and low (p = 0.034) expressivity respectively.Conclusions: 21OHD-related pediatric hyperandrogenism follows monogenic and polygenic models. The opposite behaviors in terms of clinical expressivity detected for CAPN-UCSNP44 and TNFR2-M196R rare variants suggest these variants to be sensitizing and protective factors respectively in adrenal hyperandrogenism.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"71 1","pages":"28-37"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000173739","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27863979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. 帕米膦酸钠治疗中度至重度成骨不全症儿童:注意事项。

Hormone research Pub Date : 2009-01-01 Epub Date: 2008-11-27 DOI: 10.1159/000173740

M Alharbi, G Pinto, G Finidori, J C Souberbielle, F Guillou, S Gaubicher, M Le Merrer, M Polak

{"title":"Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.","authors":"M Alharbi, G Pinto, G Finidori, J C Souberbielle, F Guillou, S Gaubicher, M Le Merrer, M Polak","doi":"10.1159/000173740","DOIUrl":"https://doi.org/10.1159/000173740","url":null,"abstract":"Background/aims: Bisphosphonates have been reported to decrease fractures related to osteogenesis imperfecta (OI). We assessed the efficacy and long-term safety of pamidronate therapy in patients with moderate-to-severe OI.Methods: We conducted an open-label uncontrolled study in 14 boys and 13 girls whose mean age was 6.8 years at baseline. Intravenous pamidronate, 1 mg/kg/day, was given for 3 consecutive days every 4 months for 2-6 years, with physical therapy and orthopedic surgery as appropriate. Mobility score, fracture rate, height, bone mineral density (BMD) and bone healing were evaluated throughout follow-up.Results: In 24 (89%) patients, the fracture rate decreased to <or=2/year and/or the mobility score improved. The remaining 3 (11%) patients continued to experience more than 2 fractures per year with mobility scores <2 despite significant BMD gains. Delayed radiographic fracture healing (>6 months) occurred in 8 (29.6%) patients; their BMD gains, baseline age and treatment duration were not significantly different from those in the other patients. Tolerance was good.Conclusion: Pamidronate with physiotherapy and orthopedic management improved outcomes without delaying fracture healing in 19 (70%) of 27 patients. Delayed fracture healing occurred in 8/27 patients. Pamidronate should be reserved for severe OI with multiple fractures and/or flattened vertebras.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"71 1","pages":"38-44"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000173740","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27863980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19